Show simple item record

dc.contributor.authorRoncero-Ramos, Irene
dc.contributor.authorGutiérrez Mariscal, Francisco Miguel
dc.contributor.authorGómez Delgado, Francisco
dc.contributor.authorVillasanta-González, Alejandro
dc.contributor.authorTorres‑Peña, J.D.
dc.contributor.authorCruz‐Ares, Silvia de la
dc.contributor.authorRangel Zúñiga, Oriol Alberto
dc.contributor.authorLuque, Raúl M.
dc.contributor.authorOrdovas, José M.
dc.contributor.authorDelgado-Lista, Javier
dc.contributor.authorPérez-Martínez, Pablo
dc.contributor.authorCamargo, Antonio
dc.contributor.authorAlcalá Díaz, Juan Francisco
dc.contributor.authorLópez-Miranda, José
dc.date.accessioned2021-11-10T07:53:21Z
dc.date.available2021-11-10T07:53:21Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/10396/22048
dc.description.abstractIn order to assess whether previous hepatic IR (Hepatic-IR fasting) and beta-cell functionality could modulate type 2 diabetes remission and the need for starting glucose- lowering treatment, newly-diagnosed type 2 diabetes participants who had never received glucose-lowering treatment (190 out of 1002) from the CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (a prospective, randomized and controlled clinical trial), were randomized to consume a Mediterranean or a low-fat diet. Type 2 diabetes remission was defined according to the American Diabetes Association recommendation for levels of HbA1c, fasting plasma glucose and 2h plasma glucose after oral glucose tolerance test, and having maintained them for at least 2 consecutive years. Patients were classified according to the median of Hepatic-IR fasting and beta-cell functionality, measured as the disposition index (DI) at baseline. Cox proportional hazards regression determined the potential for Hepatic-IR fasting and DI indexes as predictors of diabetes remission and the probability of starting pharmacological treatment after a 5-year follow-up. Low-Hepatic-IR fasting or high-DI patients had a higher probability of diabetes remission than high-Hepatic-IR fasting or low-DI subjects (HR:1.79; 95% CI 1.06_3.05; and HR:2.66; 95% CI 1.60_4.43, respectively) after a dietary intervention with no pharmacological treatment and no weight loss. The combination of low- Hepatic-IR fasting and high-DI presented the highest probability of remission (HR:4.63; 95% CI 2.00_10.70). Among patients maintaining diabetes, those with high- Hepatic-IR fasting and low-DI showed the highest risk of starting glucose-loweringes_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.sourceTranslational Research 238, 12-24 (2021)es_ES
dc.subjectType 2 Diabetes Mellituses_ES
dc.subjectInsulin resistancees_ES
dc.subjectHepatic insulin resistancees_ES
dc.subjectCORDIOPREVes_ES
dc.subjectIntervention studieses_ES
dc.titleBeta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.trsl.2021.07.001es_ES
dc.relation.projectIDJunta de Andalucía. CVI-7450es_ES
dc.relation.projectIDGobierno de España. AGL2012/39615es_ES
dc.relation.projectIDGobierno de España. AGL2015-67896-Pes_ES
dc.relation.projectIDInstituto de Salud Carlos III. PI10/01041es_ES
dc.relation.projectIDInstituto de Salud Carlos III. PI13/00023es_ES
dc.relation.projectIDInstituto de Salud Carlos III. CD16/ 00047es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record